FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2052883792> ?p ?o ?g. }

• W2052883792 endingPage "823" @default.
• W2052883792 startingPage "816" @default.
• W2052883792 abstract "Purpose The primary aim of this study was to assess pulmonary radiation toxicity quantitatively in patients who received thoracic radiotherapy combined with induction and/or concurrent chemotherapy with or without taxanes for esophageal cancer. Methods and Materials The study subjects were 139 patients treated at the University of Texas M.D. Anderson Cancer Center for esophageal cancer and who had undergone [18F]-fluorodeoxyglucose positron emission tomography/computed tomography between November 1, 2003 and December 15, 2007 for disease restaging after chemoradiotherapy. The patients were grouped into those who had not received taxanes (Group 1), those who had received induction or concurrent taxanes (Group 2), and those who had received both induction and concurrent taxanes (Group 3). Clinical pulmonary toxicity was scored using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3. Linear regression was applied to the fluorodeoxyglucose uptake vs. radiation dose to determine the pulmonary metabolic radiation response (PMRR) for each case. The clinical toxicity scores and PMRR among the groups were evaluated for significance differences. Results The crude rate of pneumonitis symptoms was 46%, 62%, and 74% for Group 1, 2, and 3, respectively. The analysis of variance test of log(PMRR) by treatment was significant (p = .0046). Group 3 had a 61% greater PMRR compared with Group 1 (p = .002). Group 2 had a 38% greater PMRR compared with Group 1 (p = .015). Finally, Group 3 had a 17% greater PMRR compared with Group 2 (p = .31). A PMRR enhancement ratio of 1.60 (95% confidence interval, 1.19–2.14) was observed for Group 3 vs. Group 1. Conclusion Patients given induction and concurrent taxane chemotherapy had a significantly greater PMRR and clinical pneumonitis symptoms compared with the patients whose chemotherapy regimen did not include taxanes. The primary aim of this study was to assess pulmonary radiation toxicity quantitatively in patients who received thoracic radiotherapy combined with induction and/or concurrent chemotherapy with or without taxanes for esophageal cancer. The study subjects were 139 patients treated at the University of Texas M.D. Anderson Cancer Center for esophageal cancer and who had undergone [18F]-fluorodeoxyglucose positron emission tomography/computed tomography between November 1, 2003 and December 15, 2007 for disease restaging after chemoradiotherapy. The patients were grouped into those who had not received taxanes (Group 1), those who had received induction or concurrent taxanes (Group 2), and those who had received both induction and concurrent taxanes (Group 3). Clinical pulmonary toxicity was scored using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3. Linear regression was applied to the fluorodeoxyglucose uptake vs. radiation dose to determine the pulmonary metabolic radiation response (PMRR) for each case. The clinical toxicity scores and PMRR among the groups were evaluated for significance differences. The crude rate of pneumonitis symptoms was 46%, 62%, and 74% for Group 1, 2, and 3, respectively. The analysis of variance test of log(PMRR) by treatment was significant (p = .0046). Group 3 had a 61% greater PMRR compared with Group 1 (p = .002). Group 2 had a 38% greater PMRR compared with Group 1 (p = .015). Finally, Group 3 had a 17% greater PMRR compared with Group 2 (p = .31). A PMRR enhancement ratio of 1.60 (95% confidence interval, 1.19–2.14) was observed for Group 3 vs. Group 1. Patients given induction and concurrent taxane chemotherapy had a significantly greater PMRR and clinical pneumonitis symptoms compared with the patients whose chemotherapy regimen did not include taxanes." @default.
• W2052883792 created "2016-06-24" @default.
• W2052883792 creator A5000178399 @default.
• W2052883792 creator A5002734619 @default.
• W2052883792 creator A5003799076 @default.
• W2052883792 creator A5042097135 @default.
• W2052883792 creator A5044064524 @default.
• W2052883792 creator A5047100062 @default.
• W2052883792 creator A5072790661 @default.
• W2052883792 creator A5078177475 @default.
• W2052883792 creator A5088499112 @default.
• W2052883792 creator A5090115592 @default.
• W2052883792 date "2010-03-01" @default.
• W2052883792 modified "2023-09-24" @default.
• W2052883792 title "Induction and Concurrent Taxanes Enhance Both the Pulmonary Metabolic Radiation Response and the Radiation Pneumonitis Response in Patients With Esophagus Cancer" @default.
• W2052883792 cites W1935541780 @default.
• W2052883792 cites W1966974891 @default.
• W2052883792 cites W1968626722 @default.
• W2052883792 cites W1973277978 @default.
• W2052883792 cites W1973712834 @default.
• W2052883792 cites W1981296302 @default.
• W2052883792 cites W2000623747 @default.
• W2052883792 cites W2006348652 @default.
• W2052883792 cites W2029679244 @default.
• W2052883792 cites W2036274321 @default.
• W2052883792 cites W2047868065 @default.
• W2052883792 cites W2048716754 @default.
• W2052883792 cites W2051753748 @default.
• W2052883792 cites W2051894533 @default.
• W2052883792 cites W2053220020 @default.
• W2052883792 cites W2053386624 @default.
• W2052883792 cites W2062462385 @default.
• W2052883792 cites W2094229486 @default.
• W2052883792 cites W2099104461 @default.
• W2052883792 cites W2103484106 @default.
• W2052883792 cites W2111274038 @default.
• W2052883792 cites W2111418742 @default.
• W2052883792 cites W2119298887 @default.
• W2052883792 cites W2124868198 @default.
• W2052883792 cites W2128003170 @default.
• W2052883792 cites W2128922346 @default.
• W2052883792 cites W2138389852 @default.
• W2052883792 cites W2140775860 @default.
• W2052883792 cites W2147014171 @default.
• W2052883792 cites W2154094988 @default.
• W2052883792 cites W2154335454 @default.
• W2052883792 cites W2167417984 @default.
• W2052883792 cites W4247128285 @default.
• W2052883792 doi "https://doi.org/10.1016/j.ijrobp.2009.02.059" @default.
• W2052883792 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3696888" @default.
• W2052883792 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19525073" @default.
• W2052883792 hasPublicationYear "2010" @default.
• W2052883792 type Work @default.
• W2052883792 sameAs 2052883792 @default.
• W2052883792 citedByCount "25" @default.
• W2052883792 countsByYear W20528837922012 @default.
• W2052883792 countsByYear W20528837922013 @default.
• W2052883792 countsByYear W20528837922014 @default.
• W2052883792 countsByYear W20528837922015 @default.
• W2052883792 countsByYear W20528837922016 @default.
• W2052883792 countsByYear W20528837922017 @default.
• W2052883792 countsByYear W20528837922019 @default.
• W2052883792 countsByYear W20528837922020 @default.
• W2052883792 countsByYear W20528837922021 @default.
• W2052883792 crossrefType "journal-article" @default.
• W2052883792 hasAuthorship W2052883792A5000178399 @default.
• W2052883792 hasAuthorship W2052883792A5002734619 @default.
• W2052883792 hasAuthorship W2052883792A5003799076 @default.
• W2052883792 hasAuthorship W2052883792A5042097135 @default.
• W2052883792 hasAuthorship W2052883792A5044064524 @default.
• W2052883792 hasAuthorship W2052883792A5047100062 @default.
• W2052883792 hasAuthorship W2052883792A5072790661 @default.
• W2052883792 hasAuthorship W2052883792A5078177475 @default.
• W2052883792 hasAuthorship W2052883792A5088499112 @default.
• W2052883792 hasAuthorship W2052883792A5090115592 @default.
• W2052883792 hasBestOaLocation W20528837922 @default.
• W2052883792 hasConcept C121608353 @default.
• W2052883792 hasConcept C126322002 @default.
• W2052883792 hasConcept C197934379 @default.
• W2052883792 hasConcept C2776256026 @default.
• W2052883792 hasConcept C2777714996 @default.
• W2052883792 hasConcept C2777793932 @default.
• W2052883792 hasConcept C2778424827 @default.
• W2052883792 hasConcept C2779524853 @default.
• W2052883792 hasConcept C2779742542 @default.
• W2052883792 hasConcept C2781047374 @default.
• W2052883792 hasConcept C29730261 @default.
• W2052883792 hasConcept C2989005 @default.
• W2052883792 hasConcept C44249647 @default.
• W2052883792 hasConcept C509974204 @default.
• W2052883792 hasConcept C71924100 @default.
• W2052883792 hasConcept C90924648 @default.
• W2052883792 hasConceptScore W2052883792C121608353 @default.
• W2052883792 hasConceptScore W2052883792C126322002 @default.
• W2052883792 hasConceptScore W2052883792C197934379 @default.
• W2052883792 hasConceptScore W2052883792C2776256026 @default.
• W2052883792 hasConceptScore W2052883792C2777714996 @default.
• W2052883792 hasConceptScore W2052883792C2777793932 @default.

• next